Core Viewpoint - Rapid Dose Therapeutics Corp. intends to extend the maturity date of its outstanding secured convertible notes from November 30, 2025, to November 30, 2026, as part of a strategic financial maneuver to manage its debt obligations [1]. Financing Details - The financing involved an offering of units priced at $1.00 per unit, each consisting of $1.00 principal amount of notes convertible at $0.17 per share, along with five common share purchase warrants with an exercise price between $0.14 and $0.17 per share, expiring on November 30, 2025. The total principal amount of notes issued was $3,134,445, along with 15,672,225 warrants [2]. Extension Agreement - Noteholders holding $3,084,445 of notes have agreed to extend the maturity date and the expiry date of their accompanying warrants to November 30, 2026, with an adjusted exercise price of $0.16. An extension fee of 5% will be paid in common shares at a price of $0.16 per share. One noteholder with a $50,000 note will receive cash repayment instead of an extension [3]. Interest Rate Adjustment - The interest rate on the notes will increase from 12% to 18% per annum, calculated and compounded monthly, with interest payable quarterly in arrears in common shares based on the closing market price on the Canadian Securities Exchange [4]. Accrued Interest Payment - The company plans to issue common shares to satisfy accrued and unpaid interest totaling $62,860.65 on the notes, due on the initial maturity date of November 30, 2025. This issuance is expected to occur no later than December 15, 2025 [5]. Securities Hold Period - All securities issued under the extension and for the payment of accrued interest will be subject to a hold period of four months and one day from the date of issuance [6]. Insider Participation - Certain insiders hold a total of $1,696,371 of notes and participated in the extension. The company is relying on exemptions from valuation and minority shareholder approval requirements due to the nature of the transaction being within the related party context [7]. Company Overview - Rapid Dose Therapeutics is a Canadian biotechnology company focused on innovative drug delivery solutions, with its flagship product QuickStrip™, an orally dissolvable film that can deliver various active ingredients rapidly into the bloodstream [8].

Core Insights - Lexaria Bioscience Corp. will participate in the BIO International Convention in Boston from June 16-19, 2025, aiming to advance discussions with potential partners and investors [1][2] Company Overview - Lexaria is a global innovator in drug delivery platforms, specifically through its patented DehydraTECH® technology, which enhances drug absorption and reduces side effects [4] - The company holds 48 granted patents and has additional patents pending worldwide, showcasing a strong intellectual property portfolio [4] Event Participation - The BIO International Convention is the largest biotechnology convention globally, featuring over 1,500 exhibitors and 20,000 attendees, providing a platform for networking and collaboration [2] - Lexaria is arranging one-on-one meetings with corporate leaders in sectors such as weight loss, diabetes, and hypertension, with limited meeting slots still available [3]